Caricamento...
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer
PURPOSE: In a recent Phase II clinical trial, low dose (100 mg/kg) gemcitabine showed promise as a radiosensitiser in bladder cancer but underlying mechanisms lack elucidation. Here we investigated the mechanism of radiosensitisation by low-dose gemcitabine in bladder cancer cell lines. EXPERIMENTAL...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4216732/ https://ncbi.nlm.nih.gov/pubmed/25224279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0542 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|